<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Indian J Pharmacol</journal-id><journal-id journal-id-type="publisher-id">IJPharm</journal-id><journal-title-group><journal-title>Indian Journal of Pharmacology</journal-title></journal-title-group><issn pub-type="ppub">0253-7613</issn><issn pub-type="epub">1998-3751</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25821308</article-id><article-id pub-id-type="pmc">4375815</article-id><article-id pub-id-type="publisher-id">IJPharm-47-34</article-id><article-id pub-id-type="doi">10.4103/0253-7613.150324</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Evaluation of effects of T and N type calcium channel blockers on the electroencephalogram recordings in Wistar Albino Glaxo/Rij rats, an absence epilepsy model</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Durmus</surname><given-names>Nedim</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>G&#x000fc;lt&#x000fc;rk</surname><given-names>Sefa</given-names></name><xref ref-type="aff" rid="aff2">1</xref></contrib><contrib contrib-type="author"><name><surname>Kaya</surname><given-names>Tijen</given-names></name><xref ref-type="aff" rid="aff3">2</xref></contrib><contrib contrib-type="author"><name><surname>Demir</surname><given-names>Tuncer</given-names></name><xref ref-type="aff" rid="aff4">3</xref></contrib><contrib contrib-type="author"><name><surname>Parlak</surname><given-names>Mesut</given-names></name><xref ref-type="aff" rid="aff5">4</xref></contrib><contrib contrib-type="author"><name><surname>Altun</surname><given-names>Ahmet</given-names></name><xref ref-type="aff" rid="aff5">4</xref></contrib></contrib-group><aff id="aff1">Department of Medical Pharmacology, Hacettepe University Medical Faculty, Ankara, Turkey</aff><aff id="aff2"><label>1</label>Department of Physiology, Cumhuriyet University Medical Faculty, Sivas, Turkey</aff><aff id="aff3"><label>2</label>Department of Medical Pharmacology, Katip Celebi University Medical Faculty, &#x00130;zmir, Turkey</aff><aff id="aff4"><label>3</label>Department of Physiology, Gaziantep University Medical Faculty, Gaziantep, Turkey</aff><aff id="aff5"><label>4</label>Department of Medical Pharmacology, Cumhuriyet University Medical Faculty, Sivas, Turkey</aff><author-notes><corresp id="cor1"><bold>Correspondence to:</bold> Dr. Nedim Durmus, E-mail: <email xlink:href="drnedimdurmus@gmail.com">drnedimdurmus@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Jan-Feb</season><year>2015</year></pub-date><volume>47</volume><issue>1</issue><fpage>34</fpage><lpage>38</lpage><history><date date-type="received"><day>21</day><month>11</month><year>2013</year></date><date date-type="rev-recd"><day>03</day><month>4</month><year>2014</year></date><date date-type="accepted"><day>08</day><month>12</month><year>2014</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Indian Journal of Pharmacology</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title>Objectives:</title><p>It is suggested that excessive calcium entry into neurons is the main triggering event in the initiation of epileptic discharges. We aimed to investigate the role of T and N type calcium channels in absence epilepsy experimental model.</p></sec><sec id="st2"><title>Materials and Methods:</title><p>Wistar Albino Glaxo/Rij (WAG/Rij) rats (12&#x02013;16 weeks old) were randomly allocated into four groups; sham, mibefradil (T type calcium channel blocker), w-Conotoxin MVIIA (N type calcium channel blocker), and mibefradil + w-Conotoxin MVIIA. Beta, alpha, theta, and delta wave ratios of EEG recordings and frequency and duration of spike wave discharges (SWDs) were analyzed and compared between groups.</p></sec><sec id="st3"><title>Results:</title><p>Beta and delta recording ratios in 1 &#x003bc;M/5 &#x003bc;l mibefradil group was significantly different from basal and other dose-injected groups. Beta, alpha, and theta recordings in 0.2 &#x003bc;M/5 &#x003bc;l w-Conotoxin MVIIA group was significantly different from basal and other dose-injected groups. In w-Conotoxin MVIIA after mibefradil group, beta, alpha, and theta recording ratios were significantly different from basal and mibefradil group. Mibefradil and w-Conotoxin MVIIA significantly decreased the frequency and duration of SWDs. The decrease of frequency and duration of SWDs in mibefradil group was significantly different from w-Conotoxin MVIIA group. The frequency and duration of SWDs significantly decreased in w-Conotoxin MVIIA after mibefradil group compared with basal, mibefradil, and w-Conotoxin MVIIA groups.</p></sec><sec id="st4"><title>Conclusions:</title><p>We concluded that both T and L type calcium channels play activator roles in SWDs and have positive effects on frequency and duration of these discharges. These results are related with their central effects more than peripheral effects.</p></sec></abstract><kwd-group><title>KEY WORDS</title><kwd>Epilepsy</kwd><kwd>mibefradil</kwd><kwd>T and N type calcium channels</kwd><kwd>Wistar Albino Glaxo/Rij rats</kwd><kwd>w-Conotoxin MVIIA</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>Introduction</title><p>Epilepsy is one of the most important central nervous system disorder that affects the 1% of the world population without demographic difference and requires a chronic drug treatment.[<xref rid="ref1" ref-type="bibr">1</xref><xref rid="ref2" ref-type="bibr">2</xref>] Comorbid situations during seizure control, drug interactions, and adverse effects make it difficult to find an efficient and cheap treatment. The underlying mechanisms of epilepsy are not clear yet, thus, half of the patients that suffers from uncontrolled seizures take only symptomatic treatment.[<xref rid="ref3" ref-type="bibr">3</xref><xref rid="ref4" ref-type="bibr">4</xref>] It is suggested that excessive calcium entry into neurons is the main triggering event in the initiation of epileptic discharges.[<xref rid="ref5" ref-type="bibr">5</xref><xref rid="ref6" ref-type="bibr">6</xref>]</p><p>Wistar Albino Glaxo/Rij (WAG/Rij) rats, originally developed as an animal model of human absence epilepsy, share many electroencephalography (EEG) and behavioral characteristics resembling absence epilepsy in humans, including the similarity of action of various anti-epileptic drugs.[<xref rid="ref7" ref-type="bibr">7</xref>]</p><p>Many researches about the molecular underlying mechanisms of the epilepsy have been focused on the calcium messenger system and excessive calcium entry into the cell have been proposed to trigger the epileptic activity.[<xref rid="ref8" ref-type="bibr">8</xref>] It has been shown that extracellular calcium decreases while intracellular calcium increases during the epileptic seizures.[<xref rid="ref9" ref-type="bibr">9</xref>] Calcium channel blockers prevent the entry of calcium into the cell and they are used to restrict the ischemia.[<xref rid="ref10" ref-type="bibr">10</xref>] The modulator relation between calcium channel blockers and the epilepsy has been shown but the exact role of them in the pathophysiology of epileptic seizures has not been clarified yet.[<xref rid="ref11" ref-type="bibr">11</xref>] In this study, we aimed to investigate the role of T and N type calcium channels in absence epilepsy by using mibefradil, a T type calcium channel blocker, w-Conotoxin MVIIA, a neuronal N type calcium channel blocker and their combination in WAG/Rij rats, an absence epilepsy model by recording electroencephalogram.</p></sec><sec sec-type="materials|methods" id="sec1-2"><title>Materials and Methods</title><sec id="sec2-1"><title/><sec id="sec3-1"><title>Animals</title><p>Thirty two 12&#x02013;16-weeks-old WAG/Rij rats weighing 220 &#x000b1; 30 g were randomly assigned to one of four groups (<italic>n</italic> = 8 each group); sham (only saline injected), only mibefradil (a T type calcium channel blocker) injected group (1 &#x003bc;M/5 &#x003bc;l, 2 &#x003bc;M/5 &#x003bc;l, 4 &#x003bc;M/5 &#x003bc;l), only w-Conotoxin MVIIA (a N type calcium channel blocker) injected group (0.1 &#x003bc;M/2 &#x003bc;l, 0.2 &#x003bc;g/5 &#x003bc;l, 0.4 &#x003bc;M/2 &#x003bc;l). In the fourth group, the most effective doses of the both agents were chosen and w-Conotoxin MVIIA (0.2 &#x003bc;M/2 &#x003bc;l after mibefradil (1 &#x003bc;M/5 &#x003bc;l) were injected. All agents were given by intracerebroventricular (icv) injection.</p><p>The rats in the experimental groups were anesthetized with a combination of xylazine (3 mg/kg) and ketamin (90 mg/kg) given subcutaneously. Following anesthesia, a small area on the top of the rat's head was shaved and the area was cleaned with betadine. The rat was placed into a small animal stereotaxic apparatus. After a small midline incision on top of the head, the periosteum was removed, the stainless steel screw electrodes were implanted on the dura mater over the cortex, two in the frontal region (coordinates with skull surface flat and bregma zero&#x02013;zero: AP + 1.9; L &#x000b1; 1.5; 1.5 mm below the dura mater) and third one on the occipital region. Electrodes were attached to the skull with dental acrylic. Following surgery, animals were housed in separate cages at a temperature-controlled facility of 23 &#x000b1; 2&#x000b0;C, a 12-hour light/dark cycle (7 a. m. to 7 p. m.) and free access to water and food for 3 days with 4 mg/kg subcutaneous carprofen for analgesia. All animals were euthanized by anesthesia at the end of experimental procedure. All procedures were approved by the Cumhuriyet University Animal Ethics Committee and were conducted in accordance with the recommendations of the Guide for the Care and Use of Laboratory Animals.</p></sec><sec id="sec3-2"><title>Experimental Protocol</title><p>Before the experimental protocol, the rats were placed singly in a plexiglas cage, connected to EEG leads and were habituated to the experimental conditions for 1 hour. All baseline and test recordings were performed from 10:00 to 15:00 hour to minimize circadian variations. The rats were attached to a multichannel amplifier (EMKA Technologies, Paris, France) via the flexible recording cable. The EEG was continuously recorded in freely moving rats for totally 5 hours, 1 hour before any injection, 1 hour after solvent injection, and 3 hours after the agent injections in experimental groups and saline injection in sham group. EEGs were displayed on a computer by the IOX 2.4.2.6 Software System (EMKA Technologies, Paris, France). The EEGs were amplified and filtered between 1 and 100 Hz, digitized at 200 Hz and stored for off-line analyses. Spike wave discharges (SWDs) were detected manually in WAG/Rij rats. Numbers and durations of SWDs over 20-min time periods were calculated.</p><p>The beta, alpha, theta, and delta wave ratios of EEG recordings and the frequency and duration of SWDs were analyzed and compared between four groups.</p></sec><sec id="sec3-3"><title>Statistical Analysis</title><p>A repeated measures one-way analysis of variance (ANOVA), followed by <italic>post hoc</italic> Tukey test was used for statistical analysis. The level of statistical significance was considered to be <italic>P</italic> &#x0003c; 0.05. Independent <italic>t</italic>-test was used to assess comparisons between groups. Each EEG recording was divided into 20-min epochs, and the duration and number of SWDs were analyzed separately for each epoch; the resulting data were expressed as means &#x000b1; scanning electron microscope (SEM) for each time point.</p></sec></sec></sec><sec sec-type="results" id="sec1-3"><title>Results</title><p>There was not any significant difference between the basal beta, alpha, and delta wave ratios of EEG recordings of three experimental groups [<xref ref-type="fig" rid="F1">Figure 1</xref>]. Beta and delta recording ratios in 1 &#x003bc;M/5 &#x003bc;l mibefradil-injected group was significantly different from basal and other dose-injected animal recordings (<italic>P</italic> &#x0003c; 0.05) [<xref ref-type="fig" rid="F2">Figure 2</xref>]. Beta, alpha and theta recording ratios in 0.2 &#x003bc;M/5 &#x003bc;l w-Conotoxin MVIIA-injected group was significantly different from basal and other dose-injected animals recordings (<italic>P</italic> &#x0003c; 0.05) [<xref ref-type="fig" rid="F3">Figure 3</xref>]. In w-Conotoxin MVIIA after mibefradil group, the most effective doses of both agents (0.2 &#x003bc;M/5 &#x003bc;l and 1 &#x003bc;M/5 &#x003bc;l, respectively) were used to investigate the combination effects of both T and N type calcium channel blockers. Beta, alpha, and theta recording ratios in this group were significantly different from basal and only 1 &#x003bc;M/5 &#x003bc;l mibefradil-injected group (<italic>P</italic> &#x0003c; 0.05) [<xref ref-type="fig" rid="F4">Figure 4</xref>].</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>The basal beta, alpha, theta, and delta wave ratios of electroencephalography (EEG) recordings (mibef: Mibefradil, con: w-Conotoxin MVIIA, mibef + con: Mibefradil + w-Conotoxin MVIIA)</p></caption><graphic xlink:href="IJPharm-47-34-g001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><p>Comparison of beta, alpha, theta, and delta wave ratios of electroencephalography (EEG) recordings after different doses of mibefradil injection (1 &#x003bc;M/5 &#x003bc;l, 2 &#x003bc;M/5 &#x003bc;l and 4 &#x003bc;M/5 &#x003bc;l, intracerebroventricular (icv)). <sup>a, b</sup>Statistically different from basal, 2 &#x003bc;M/5 &#x003bc;l and 4 &#x003bc;M/5 &#x003bc;l mibefradil-injected groups (<italic>P</italic> &#x0003c; 0.05)</p></caption><graphic xlink:href="IJPharm-47-34-g002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><p>Beta, alpha, theta, and delta wave ratios of electroencephalography (EEG) recordings after different doses of w-Conotoxin MVIIA, a Statistically different from beta wave ratios of basal, 0.1 &#x003bc;M/5 &#x003bc;l and 0.4 &#x003bc;M/5 &#x003bc;l w-Conotoxin MVIIA groups (<italic>P</italic> &#x0003c; 0.05), b Statistically different from alpha wave ratios of basal, 0.1 &#x003bc;M/5 &#x003bc;l and 0.4 &#x003bc;M/5 &#x003bc;l w-Conotoxin MVIIA groups (<italic>P</italic> &#x0003c; 0.05), c Statistically different from theta wave ratios of basal, 0.1 &#x003bc;M/5 &#x003bc;l and 0.4 &#x003bc;M/5 &#x003bc;l w-konotoksin MVIIA groups (<italic>P</italic> &#x0003c; 0.05), d Statistically different from delta wave ratios of basal, 0.1 &#x003bc;M/5 &#x003bc;l ve 0.4 &#x003bc;M/5 &#x003bc;l w-konotoksin MVIIA groups (<italic>P</italic> &#x0003c; 0.05)</p></caption><graphic xlink:href="IJPharm-47-34-g003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><p>Comparison of beta, alpha, theta, and delta wave ratios of electroencephalography (EEG) recordings of w-Conotoxin MVIIA (0.2 &#x003bc;M/5 &#x003bc;l) after mibefradil injection (1 &#x003bc;M/5 &#x003bc;l, intracerebroventricular (icv)) (mibef: Mibefradil, mibef + con: Mibefradil + w-Conotoxin MVIIA). <sup>a, e</sup>Statistically different from beta and delta wave ratios of EEG recordings of only mibefradil (1 &#x003bc;M/5 &#x003bc;l) and w-Conotoxin MVIIA (0.2 &#x003bc;M/5 &#x003bc;l) after mibefradil (1 &#x003bc;M/5 &#x003bc;l) injected groups (<italic>P</italic> &#x0003c; 0.05), <sup>b,c,d,f</sup>Statistically different from basal and w-Conotoxin MVIIA (0.2 &#x003bc;M/5 &#x003bc;l) after mibefradil (1 &#x003bc;M/5 &#x003bc;l) injected groups (<italic>P</italic> &#x0003c; 0.05)</p></caption><graphic xlink:href="IJPharm-47-34-g004"/></fig><p>In sham group, there was no significant change of frequency and duration of SWDs after saline injection. Mibefradil significantly decreased the frequency and duration of SWDs (<italic>P</italic> &#x0003c; 0.05), this decrease was maximum after 120 min and returned to the basal levels after 180 min. w-Conotoxin MVIIA significantly decreased the frequency and duration of SWDs (<italic>P</italic> &#x0003c; 0.05), this decrease was maximum after 60 min and returned to the basal levels after 180 min. The decrease of frequency and duration of SWDs in only mibefradil (1 &#x003bc;/5 &#x003bc;l) injected group was significantly different from only w-Conotoxin MVIIA (0.2 &#x003bc;M/5 &#x003bc;l) injected group (<italic>P</italic> &#x0003c; 0.05). The frequency and duration of SWDs significantly decreased in w-Conotoxin MVIIA (0.2 &#x003bc;M/5 &#x003bc;l) after mibefradil (1 &#x003bc;/5 &#x003bc;l) group (<italic>P</italic> &#x0003c; 0.05), this decrease was maximum after 60 min and returned to the basal levels after 180 min. This decrease was significantly different from basal, only mibefradil (1 &#x003bc;/5 &#x003bc;l) and only w-Conotoxin MVIIA (0.2 &#x003bc;M/5 &#x003bc;l) (<italic>P</italic> &#x0003c; 0.05) [<xref ref-type="fig" rid="F5">Figure 5</xref>].</p><fig id="F5" position="float"><label>Figure 5</label><caption><p>Frequency (A, nSWDs) and duration (B, dSWDs) of spike wave discharges (SWDs) of w-Conotoxin MVIIA (0.2 &#x003bc;M/5 &#x003bc;l) after mibefradil injections (1 &#x003bc;M/5 &#x003bc;l, intracerebroventricular (icv)), <sup>a,b</sup>Statistically different from sham, only w-Conotoxin MVIIA (0.2 &#x003bc;M/5 &#x003bc;l) and w-Conotoxin MVIIA (0.2 &#x003bc;M/5 &#x003bc;l) after mibefradil (1 &#x003bc;M/5 &#x003bc;l) groups (<italic>P</italic> &#x0003c; 0.05), <sup>c,d</sup>Statistically different from sham, only mibefradil (1 &#x003bc;g/5 &#x003bc;l) and w-Conotoxin MVIIA (0.2 &#x003bc;M/5 &#x003bc;l) after mibefradil (1 &#x003bc;M/5 &#x003bc;l) groups (<italic>P</italic> &#x0003c; 0.05), <sup>e,f</sup>Statistically different from sham, only mibefradil (1 &#x003bc;g/5 &#x003bc;l) and only w-Conotoxin MVIIA (0.2 &#x003bc;M/5 &#x003bc;l) groups (<italic>P</italic> &#x0003c; 0.05)</p></caption><graphic xlink:href="IJPharm-47-34-g005"/></fig></sec><sec sec-type="discussion" id="sec1-4"><title>Discussion</title><p>The effect mechanisms of calcium channels in epileptogenesis are related with their electrophysiological, pharmacological, and bio-physiological effects and all calcium channels (L, T, P/Q, and N) are present in the brain. SWDs are especially originated from thalamus and T type channels are more than L types in this area.[<xref rid="ref12" ref-type="bibr">12</xref>] SWDs occur after the rhythmic interactions between thalamic and cortical areas and T type calcium channels have active role in these areas. Although there are important queries on the effects of ethosuximide, it is important in the depressing the T type channels in the thalamic neurons.[<xref rid="ref13" ref-type="bibr">13</xref>] Leresche <italic>et al</italic>., showed the ineffectivity of ethosuximide on low and high threshold calcium currents and its decreasing effects on the non-active sodium currents which affect the calcium activated potassium currents. These results may explain the burst firing, increase in the tonic firing and SWDs.[<xref rid="ref14" ref-type="bibr">14</xref>]</p><p>It has been suggested that BAY K8644 (calcium channel agonist) and nimodipine (dihydropyridine calcium channel blocker) have two possible mechanisms in their antagonism effects of epileptic activity. Firstly, BAY K8644 may antagonize the epileptiformic effects of nimodipine in non-convulsive epilepsy. Secondly, nimodipine may inhibit convulsions by BAY K8644. Intraperitoneal nimodipine reversed the effects of intraventriculer ejected BAY K8644[<xref rid="ref15" ref-type="bibr">15</xref>] which show the central effects of both agents. These results show the possible effects of L type calcium channels with T types in SWDs[<xref rid="ref15" ref-type="bibr">15</xref><xref rid="ref16" ref-type="bibr">16</xref>] and the induction of L type channels by T types during the inhibition of SWDs. Although, there are studies investigating the role of L type calcium channels in the firing mode of talamocortical neurons,[<xref rid="ref17" ref-type="bibr">17</xref>] the role of T and N type calcium channels is not clear in the generalized absence epilepsy.</p><p>In this study, we aimed to clarify the effects of T and N type calcium channel blockers on the pathophysiology of absence epileptic seizures by recording electroencephalogram. Beta and delta recording ratios in 1 &#x003bc;M/5 &#x003bc;l mibefradil-injected group was significantly different from basal and other dose-injected animals recordings. Beta, alpha, and theta recording ratios in 0.2 &#x003bc;M/5 &#x003bc;l w-Conotoxin MVIIA-injected group was significantly different from basal and other dose-injected animals recordings. In w-Conotoxin MVIIA after mibefradil group, beta, alpha, and theta recording ratios were significantly from basal and only mibefradil-injected group. Mibefradil and w-Conotoxin MVIIA significantly decreased the frequency and duration of SWDs. The decrease of frequency and duration of SWDs in only mibefradil-injected group was significantly different from the only w-Conotoxin MVIIA-injected group. The frequency and duration of SWDs significantly decreased in w-Conotoxin MVIIA after mibefradil group compared with basal, only mibefradil and only w-Conotoxin MVIIA groups.</p><p>Spike wave discharges in electroencephalogram are one of the key symptoms of generalized absence epilepsy. Low-voltage-activated or T type calcium channel flows are thought to play significant role in thalamic neuronal rhythmicfiring properties. It is known that talamocortical transmission cells are hyperpolarized during wakefulness to faint.[<xref rid="ref18" ref-type="bibr">18</xref><xref rid="ref19" ref-type="bibr">19</xref><xref rid="ref20" ref-type="bibr">20</xref>]</p><p>The current amplitude of T type calcium channels were increased in a rat absence epilepsy model developed by Marescaux <italic>et al</italic>.[<xref rid="ref21" ref-type="bibr">21</xref>] Ethosuximide, a specific anti-absence drug, blocks T type calcium channels with another mechanism.[<xref rid="ref22" ref-type="bibr">22</xref>] Ethosuximide is used in the treatment of absence epilepsy and it is known that it blocks the T type calcium channels by inhibiting the calcium entry especially in the thalamic area neurons and low threshold calcium increase is depressed and burst firing is inhibited. The effects of ethosuximide on SWDs have been shown in human and animals by <italic>in vivo</italic> and <italic>in vitro</italic> studies.[<xref rid="ref23" ref-type="bibr">23</xref>]</p><p>Van Luijtelaar <italic>et al</italic>.,[<xref rid="ref16" ref-type="bibr">16</xref>] used L and T type calcium channel modulators BAY K8644, nimodipine and ethosuximide in WAG-Rij rats, a genetic absence epilepsy model. They also investigated the role of calcium channel subunits by using w-Conotoxin GVIA and w-Conotoxin MVIIC, an N type calcium channel blocker and a P/Q type calcium channel blocker, respectively. Both of the calcium channel subunits are present in the central nervous system. They showed the relations between the SWDs and P/Q channel subunits in these rats.[<xref rid="ref24" ref-type="bibr">24</xref>]</p><p>Although, calcium channel blockers are generally thought to be anti-convulsive,[<xref rid="ref21" ref-type="bibr">21</xref>] it has been shown that T and L type calcium channel blockers may have opposite effects in non-convulsive epilepsy.[<xref rid="ref16" ref-type="bibr">16</xref>] Besides, calcium channel blockers and openers affect the central parameters like blood pressure by their peripheral effects on skeletal and cardiac systems. These agents affect the seizure activity like SWDs related with their peripheral effects.[<xref rid="ref25" ref-type="bibr">25</xref>]</p><p>In conclusion, we have showed that both T and L type calcium channels play activator roles in SWDs and have positive effects on the frequency and duration of these discharges. These results are related with their central effects more than peripheral effects.</p></sec></body><back><ack><title>Acknowledgement</title><p>This study was funded in full by Cumhuriyet University Scientific Project Support Unit, grant number [T-384].</p></ack><fn-group><fn fn-type="supported-by"><p><bold>Source of Support:</bold> Nil.</p></fn><fn fn-type="conflict"><p><bold>Conflict of Interest:</bold> No.</p></fn></fn-group><ref-list><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Usunoff</surname><given-names>G</given-names></name><name><surname>Atsev</surname><given-names>E</given-names></name><name><surname>Tchavdarow</surname><given-names>D</given-names></name></person-group><article-title>On the mechanisms of picrotoksin epileptic seizures (macro- and micro-electrode investigations)</article-title><source>Electroencephalogr Clin Neurophysiol</source><year>1969</year><volume>27</volume><fpage>444</fpage><pub-id pub-id-type="pmid">4186745</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blumenfeld</surname><given-names>H</given-names></name></person-group><article-title>From molecules to networks: Cortical/subcortical interactions in the pathophysiology of idiopathic generalized epilepsy</article-title><source>Epilepsia</source><year>2003</year><volume>44</volume><fpage>7</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">12752456</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobow</surname><given-names>K</given-names></name><name><surname>Auvin</surname><given-names>S</given-names></name><name><surname>Jensen</surname><given-names>F</given-names></name><name><surname>L&#x000f6;scher</surname><given-names>W</given-names></name><name><surname>Mody</surname><given-names>I</given-names></name><name><surname>Potschka</surname><given-names>H</given-names></name><etal/></person-group><article-title>Finding a better drug for epilepsy: Antiepileptogenesis targets</article-title><source>Epilepsia</source><year>2012</year><volume>53</volume><fpage>1868</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">23061663</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grosso</surname><given-names>S</given-names></name><name><surname>Galimberti</surname><given-names>D</given-names></name><name><surname>Vezzosi</surname><given-names>P</given-names></name><name><surname>Farnetani</surname><given-names>M</given-names></name><name><surname>Di Bartolo</surname><given-names>RM</given-names></name><name><surname>Bazzotti</surname><given-names>S</given-names></name><etal/></person-group><article-title>Childhood absence epilepsy: Evolution and prognostic factors</article-title><source>Epilepsia</source><year>2005</year><volume>46</volume><fpage>1796</fpage><lpage>801</lpage><pub-id pub-id-type="pmid">16302860</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacAllister</surname><given-names>WS</given-names></name><name><surname>Schaffer</surname><given-names>SG</given-names></name></person-group><article-title>Neuropsychological deficits in childhood epilepsy syndromes</article-title><source>Neuropsychol Rev</source><year>2007</year><volume>17</volume><fpage>427</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">17963043</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wirrell</surname><given-names>EC</given-names></name><name><surname>Camfield</surname><given-names>CS</given-names></name><name><surname>Camfield</surname><given-names>PR</given-names></name><name><surname>Dooley</surname><given-names>JM</given-names></name><name><surname>Gordon</surname><given-names>KE</given-names></name><name><surname>Smith</surname><given-names>B</given-names></name></person-group><article-title>Long-term psychosocial outcome in typical absence epilepsy. Sometimes a wolf in sheeps&#x02019; clothing</article-title><source>Arch Pediatr Adolesc Med</source><year>1997</year><volume>151</volume><fpage>152</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9041870</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coenen</surname><given-names>AM</given-names></name><name><surname>Van Luijtelaar</surname><given-names>EL</given-names></name></person-group><article-title>Genetic animal models for absence epilepsy: A review of the VVAG/Rij strain of rats</article-title><source>Behav Genet</source><year>2003</year><volume>33</volume><fpage>635</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">14574120</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dur&#x000f3;n</surname><given-names>RM</given-names></name><name><surname>Medina</surname><given-names>MT</given-names></name><name><surname>Mart&#x000ed;nez-Ju&#x000e1;rez</surname><given-names>IE</given-names></name><name><surname>Bailey</surname><given-names>JN</given-names></name><name><surname>Perez-Gosiengfiao</surname><given-names>KT</given-names></name><name><surname>Ramos-Ram&#x000ed;rez</surname><given-names>R</given-names></name><etal/></person-group><article-title>Seizures of idiopathic generalized epilepsies</article-title><source>Epilepsia</source><year>2005</year><volume>46</volume><fpage>34</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">16302874</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeLorenzo</surname><given-names>RJ</given-names></name><name><surname>Sun</surname><given-names>DA</given-names></name><name><surname>Deshpande</surname><given-names>LS</given-names></name></person-group><article-title>Erratum to &#x0201c;Cellular mechanisms underlying acquired epilepsy: The calcium hypothesis of the induction and maintenance of epilepsy.&#x0201d; [Pharmacol. Ther. 105 (3) (2005) 229-266]</article-title><source>Pharmacol Ther</source><year>2006</year><volume>111</volume><fpage>288</fpage><lpage>325</lpage><pub-id pub-id-type="pmid">16832874</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiner</surname><given-names>DA</given-names></name></person-group><article-title>Calcium channel blockers</article-title><source>Med Clin North Am</source><year>1988</year><volume>72</volume><fpage>83</fpage><lpage>115</lpage><pub-id pub-id-type="pmid">3276988</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ku&#x00142;ak</surname><given-names>W</given-names></name><name><surname>Sobaniec</surname><given-names>W</given-names></name><name><surname>Wojtal</surname><given-names>K</given-names></name><name><surname>Czuczwar</surname><given-names>SJ</given-names></name></person-group><article-title>Calcium modulation in epilepsy</article-title><source>Pol J Pharmacol</source><year>2004</year><volume>56</volume><fpage>29</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">15047975</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carbone</surname><given-names>E</given-names></name><name><surname>Lux</surname><given-names>HD</given-names></name></person-group><article-title>Low and high voltage activated Ca2q channels in vertebrate cultured neurons: Properties and functions</article-title><source>Exp Brain Res</source><year>1986</year><volume>14</volume><fpage>1</fpage><lpage>8</lpage></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varadi</surname><given-names>G</given-names></name><name><surname>Mori</surname><given-names>Y</given-names></name><name><surname>Mikala</surname><given-names>G</given-names></name><name><surname>Schwartz</surname><given-names>A</given-names></name></person-group><article-title>Molecular determinants of Ca2+channel function and drug action</article-title><source>Trends Pharmacol Sci</source><year>1995</year><volume>16</volume><fpage>43</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">7762082</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leresche</surname><given-names>N</given-names></name><name><surname>Parri</surname><given-names>HR</given-names></name><name><surname>Erdemli</surname><given-names>G</given-names></name><name><surname>Guyon</surname><given-names>A</given-names></name><name><surname>Turner</surname><given-names>JP</given-names></name><name><surname>Williams</surname><given-names>SR</given-names></name><etal/></person-group><article-title>On the action of the anti-absence drug ethosuximide in the rat and cat thalamus</article-title><source>J Neurosci</source><year>1998</year><volume>18</volume><fpage>4842</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">9634550</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Luijtelaar</surname><given-names>G</given-names></name><name><surname>Wiaderna</surname><given-names>D</given-names></name><name><surname>Elants</surname><given-names>C</given-names></name><name><surname>Scheenen</surname><given-names>W</given-names></name></person-group><article-title>Opposite effects of T- and L-type Ca (2+) channels blockers in generalized absence epilepsy</article-title><source>Eur J Pharmacol</source><year>2000</year><volume>406</volume><fpage>381</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11040345</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Luijtelaar</surname><given-names>EL</given-names></name><name><surname>Ates</surname><given-names>N</given-names></name><name><surname>Coenen</surname><given-names>AM</given-names></name></person-group><article-title>Role of L-type calcium channel modulation in nonconvulsive epilepsy in rats</article-title><source>Epilepsia</source><year>1995</year><volume>36</volume><fpage>86</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">7528137</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huguenard</surname><given-names>JR</given-names></name></person-group><article-title>Low-threshold calcium currents in central nervous system neurons</article-title><source>Annu Rev Physiol</source><year>1996</year><volume>58</volume><fpage>329</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">8815798</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steriade</surname><given-names>M</given-names></name><name><surname>McCormick</surname><given-names>DA</given-names></name><name><surname>Sejnowski</surname><given-names>TJ</given-names></name></person-group><article-title>Thalamocortical oscillations in the sleeping and aroused brain</article-title><source>Science</source><year>1993</year><volume>262</volume><fpage>679</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">8235588</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCormick</surname><given-names>DA</given-names></name><name><surname>Bal</surname><given-names>T</given-names></name></person-group><article-title>Sleep and arousal: Thalamocortical mechanisms</article-title><source>Annu Rev Neurosci</source><year>1997</year><volume>20</volume><fpage>185</fpage><lpage>215</lpage><pub-id pub-id-type="pmid">9056712</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Ree</surname><given-names>M</given-names></name><name><surname>Wijnberg</surname><given-names>I</given-names></name></person-group><article-title>A review on epilepsy in the horse and the potential of Ambulatory EEG as a diagnostic tool</article-title><source>Vet Q</source><year>2012</year><volume>32</volume><fpage>159</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">23163553</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marescaux</surname><given-names>C</given-names></name><name><surname>Vergnes</surname><given-names>M</given-names></name><name><surname>Depauli</surname><given-names>A</given-names></name></person-group><article-title>Genetic absence epilepsy in rats from Strasbourg-a review</article-title><source>J Neural Transm Suppl</source><year>1992</year><volume>35</volume><fpage>37</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">1512594</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broicher</surname><given-names>T</given-names></name><name><surname>Seidenbecher</surname><given-names>T</given-names></name><name><surname>Meuth</surname><given-names>P</given-names></name><name><surname>Munsch</surname><given-names>T</given-names></name><name><surname>Meuth</surname><given-names>SG</given-names></name><name><surname>Kanyshkova</surname><given-names>T</given-names></name><etal/></person-group><article-title>T-current related effects of antiepileptic drugs and a Ca2+channel antagonist on thalamic relay and local circuit interneurons in a rat model of absence epilepsy</article-title><source>Neuropharmacology</source><year>2007</year><volume>53</volume><fpage>431</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">17675191</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kostyuk</surname><given-names>PG</given-names></name><name><surname>Molokanova</surname><given-names>EA</given-names></name><name><surname>Pronchuk</surname><given-names>NF</given-names></name><name><surname>Savchenko</surname><given-names>AN</given-names></name><name><surname>Verkhratsky</surname><given-names>AN</given-names></name></person-group><article-title>Different action of ethosuximide on low- and high-threshold calcium currents in rat sensory neurons</article-title><source>Neuroscience</source><year>1992</year><volume>51</volume><fpage>755</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">1336826</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fletcher</surname><given-names>CF</given-names></name><name><surname>Frankel</surname><given-names>WN</given-names></name></person-group><article-title>Ataxic mouse mutants and molecular mechanisms of absence epilepsy</article-title><source>Hum Mol Genet</source><year>1999</year><volume>8</volume><fpage>1907</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">10469844</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zapater</surname><given-names>P</given-names></name><name><surname>Javaloy</surname><given-names>J</given-names></name><name><surname>Rom&#x000e1;n</surname><given-names>JF</given-names></name><name><surname>Vidal</surname><given-names>MT</given-names></name><name><surname>Horga</surname><given-names>JF</given-names></name></person-group><article-title>Anticonvulsant effects of nimodipine and two novel dihydropyridines (PCA 50922 and PCA 50941) against seizures elicited by pentylenetetrazole and electroconvulsive shock in mice</article-title><source>Brain Res</source><year>1998</year><volume>796</volume><fpage>311</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">9689485</pub-id></element-citation></ref></ref-list></back></article>